转化医学在原发性肝癌研究中的应用和展望

Model of translational medicine for hepatocelluar carcinoma

原发性肝癌是一种全球性疾病,是世界第二大癌症相关死亡病因,全球范围内其发病率仍在上升.中国是肝癌大国,全世界55％的肝癌患者在中国,且中国的大多数肝癌患者在确诊时已处于晚期,失去了最佳治疗时机.原发性肝癌对大部分标准化疗方案不敏感,迄今为止被证实唯一有效的分子靶向药物仅有索拉菲尼.当前,原发性肝癌的基础研究集中于以下方面：（1）探索用于早期诊断的生物学标志物;（2）探求分子标志物与影像学、组织学特征的相关性;（3）鉴定新药物靶标和探索个体化疗法.本文主要探讨原发性肝癌基础研究领域的突破进展,对可能实现临床应用转化的研究进展进行综述.

Hepatocellular carcinoma （HCC） is a global problem and the second most common cause of cancer related deaths worldwide.Its global incidence is still on the rise.The incidence of HCC in China is high and approximately 55% of overall cases happened in China.Moreover,there is an undeniable fact that a majority of HCCs are diagnosed at advanced stages when the optimal treatment timing is missed,and advanced HCCs are resistant to most standard chemotherapy regimens.Sorafenib is the only systemic drug approved for the treatment of advanced HCCs.The current researches of HCC included the following components：discovery of biomarkers for early diagnosis,correlation of molecular signatures with radiologic/histologic features,characterization of new druggable targets and personalization of therapy based on individual tumor biology.In this review we focus on advances which have the potential to make transition from bench to bedside and ultimately be beneficial for patients with HCC.